AREV Life Sciences Global Corp

OTC: AREVF · Healthcare · Medical - Pharmaceuticals

Canadian filerHQ Coquitlam, BCReports USD

#1076 of 1,394 Healthcare companies by revenuebottom-quartile growth

EA Score

——

FH —DQ —GM —SS 49

v0.1 · 5/100 weight · pillars only

↑ workforce scale, growth stability · ↓ return on assets, Altman-Z

Methodology →

Revenue TTM

$5.3k

Rev growth YoY (TTM)

-96.3%

Net income (FY)

-$1.1M

Employees

19,534

Market cap

$15.9k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$37.7k49.1k CAD2022

Net income-$1.1M-1.4M CAD2022

Operating income-$1.1M-1.4M CAD2022

Total assets$186.5k252.6k CAD2022

Liabilities$889.9k1.2M CAD2022

Equity-$703.3k-952.6k CAD2022

Revenue trend

FY2017 – FY2022 · USD

FY17

FY18

$146.7k

FY19

$142.1k

FY20

$203.4k

FY21

$37.7k

FY22

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

AREV Life Sciences Global Corp booked $37.7k in FY2022 revenue, contracting 81% year over year — slower than 88% of Healthcare companies we track, at a -2940.4% net margin.

Peers · Healthcare

Regenicin, Inc.——Lattice Biologics Ltd.——Wuhan General Group (China), Inc.——Aeolus Pharmaceuticals, Inc.——

Key facts

CEOMichael C. Withrow

SectorHealthcare

IndustryMedical - Pharmaceuticals

HeadquartersCoquitlam, BC

ExchangeOTC: AREVF

Employees19,534

IPO date2019-04-30

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.